NCT04205656View on ClinicalTrials.gov

Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2024

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

Leukocyte-Poor Platelet Rich Plasma (LP-PRP)

Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.

BIOLOGICAL

Bone Marrow Concentrate (BMC)

Participants will have a knee injected with BMC stem cells harvested from the iliac crest

OTHER

Control group (Placebo)

Participants will undergo ACLR surgery with no injection into their knee.

Trial Locations (1)

81657-5242

181 West Meadow Drive, Suite 1000, Vail

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Office of Naval Research (ONR)

FED

lead

Steadman Philippon Research Institute

OTHER

NCT04205656 - Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction | Biotech Hunter | Biotech Hunter